Bridgeway Capital Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Bridgeway Capital Management’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-31,900	Closed	-$119K	–	1328
2024 Q3	$119K	Hold	31,900	–	–	﹤0.01%	1137
2024 Q2	$179K	Hold	31,900	–	–	﹤0.01%	1075
2024 Q1	$167K	Hold	31,900	–	–	﹤0.01%	1136
2023 Q4	$167K	Buy	+31,900	New	+$315K	﹤0.01%	1173
2018 Q3	–	Sell	-6,600	Closed	-$499K	–	1484
2018 Q2	$499K	Hold	6,600	–	–	0.01%	1130
2018 Q1	$348K	Hold	6,600	–	–	﹤0.01%	1171
2017 Q4	$353K	Hold	6,600	–	–	﹤0.01%	1176
2017 Q3	$394K	Hold	6,600	–	–	﹤0.01%	1150
2017 Q2	$521K	Buy	+6,600	New	+$540K	0.01%	1082
2015 Q4	–	Sell	-15,150	Closed	-$1.12M	–	1503
2015 Q3	$1.12M	Sell	15,150 -16,968	-53%	-$1.41M	0.02%	700
2015 Q2	$2.6M	Buy	32,118 +150	+0.5%	+$9.77K	0.05%	424
2015 Q1	$1.34M	Hold	31,968	–	–	0.03%	675
2014 Q4	$496K	Buy	31,968 +15,000	+88%	+$192K	0.01%	1068
2014 Q3	$215K	Buy	+16,968	New	+$210K	0.01%	1328

Other funds holding EGRX

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

SLG

Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

AIC

Archer Investment Corporation Carmel, Indiana $469M AUM 19.1% 1-Year Est. Return

Credit Agricole Montrouge Cedex, France $38.1B AUM

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Bridgeway Capital Management's EGRX Position: Q4 2024 in Review

Bridgeway Capital Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2024, closing a stake of 31,900 shares — an estimated $119K sold.

Bridgeway Capital Management first reported a position in EGRX in Q3 2014 and held it in 14 quarters. The position peaked at $2.6M in Q2 2015. 9 funds tracked by Wall St. Rank hold EGRX as of Q4 2024.

Bridgeway Capital Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2024 after selling out during the quarter.
Bridgeway Capital Management sold 31,900 Eagle Pharmaceuticals, Inc. shares in Q4 2024, an estimated $119K.
Bridgeway Capital Management first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2014 and held it in 14 quarters.
Bridgeway Capital Management's Eagle Pharmaceuticals, Inc. position peaked at $2.6M in Q2 2015.
9 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2024.

Based on Bridgeway Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.